Two Sigma Investments, LP Bristol Myers Squibb CO Transaction History

Two Sigma Investments, LP

$40.3 Billion
Q1 2024

A detailed history of Two Sigma Investments, LP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Two Sigma Investments, LP holds 4,597,331 shares of BMY stock, worth $191 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares

4,597,331

Previous 4,897,656 6.13%

Holding current value

$191 Million

Previous $251 Million 0.79%

% of portfolio

0.62%

Previous 0.61%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $14.4 Million - $16.3 Million	-300,325 Reduced 6.13%	4,597,331 $249 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $40.5 Million - $48.3 Million	835,524 Added 20.57%	4,897,656 $251 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $50 Million - $56 Million	864,371 Added 27.03%	4,062,132 $236 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $86.2 Million - $95.7 Million	1,352,338 Added 73.28%	3,197,761 $204 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $63.5 Million - $72 Million	965,651 Added 109.76%	1,845,423 $128 Million

Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $35.1 Million - $41.6 Million	512,671 Added 139.65%	879,772 $63.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $327,991 - $194 Million	-2,523,011 Reduced 87.3%	367,101 $26.1 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $2.73 Million - $3 Million	-37,541 Reduced 1.28%	2,890,112 $223 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $58.5 Million - $70.2 Million	-952,148 Reduced 24.54%	2,927,653 $214 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $9.35 Million - $10.9 Million	174,412 Added 4.71%	3,879,801 $242 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $2.05 Million - $2.4 Million	34,680 Added 0.94%	3,705,389 $219 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $191 Million - $208 Million	3,078,135 Added 519.45%	3,670,709 $245 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $31.6 Million - $35.6 Million	533,016 Added 894.95%	592,574 $37.4 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $53.1 Million - $60.2 Million	-920,457 Reduced 93.92%	59,558 $3.69 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $16.3 Million - $18.1 Million	283,829 Added 40.77%	980,015 $59.1 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $33.3 Million - $38.9 Million	606,600 Added 677.11%	696,186 $40.9 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $55.8 Million - $81.2 Million	-1,203,503 Reduced 93.07%	89,586 $4.99 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $32.2 Million - $42 Million	-653,984 Reduced 33.59%	1,293,089 $83 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $36.2 Million - $42.9 Million	-846,469 Reduced 30.3%	1,947,073 $98.7 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $48.7 Million - $53.8 Million	-1,091,042 Reduced 28.09%	2,793,542 $127 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $149 Million - $177 Million	3,291,232 Added 554.68%	3,884,584 $185 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $6.37 Million - $8.26 Million	130,669 Added 28.24%	593,352 $30.8 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $42.3 Million - $47.7 Million	-765,613 Reduced 62.33%	462,683 $28.7 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $16.4 Million - $18.9 Million	273,423 Added 28.63%	1,228,296 $77.7 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $45.4 Million - $49.6 Million	-758,234 Reduced 44.26%	954,873 $58.5 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $94.6 Million - $109 Million	1,713,107	1,713,107 $109 Million

Others Institutions Holding BMY

# of Institutions

2,554

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $88.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Bristol Myers Squibb CO Transaction History